Intensity Therapeutics 주식 (NASDAQ: INTS)

에 대한 최신 뉴스 Intensity Therapeutics (NASDAQ:INTS) 주식

Intensity Therapeutics

Intensity Therapeutics Inc is a clinical-stage biotechnology company pioneering a new immune-based approach to treat solid tumor cancers. The company leverages its DfuseRxtechnology platform to create new, proprietary drug formulations that, following direct injection, rapidly disperse throughout a tumor and diffuse therapeutic agents into cancer cells. Intensity's product candidates have the potential to induce an adaptive systemic immune response that not only attacks the injected tumor, but also non-injected tumors. Their pipeline is focused on realizing the full potential of INT230-6 in metastatic and local disease settings to help cancer patients with unmet medical need.

Intensity Therapeutics, Inc. - Common Stock

Intensity Therapeutics Inc

RBC Capital analyst Nelson Ng maintains Methanex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MEOH#NASDAQ">MEOH</a>) with a Sector Perform and lowers the price target from $55 to $50.

News

Price Target

Analyst Ratings

MEOH

RBC Capital Maintains Sector Perform on Methanex, Lowers Price Target to $50

Bitcoin's (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) resilience is fueling speculation that it may be evolving into an equity alternative, a shift that could make it more stable and attractive during <a href="https://www.benzinga.com/content/45132992/3-retail-stocks-that-desperately-need-a-tariff-break">broader market turbulence</a>.
What Happened: In an X <a href="https://x.com/nicrypto/status/1917923721722863988">post</a> on May 1, CoinBureau CEO and co-founder Nic Puckrin referenced BlackRock's Robert Mitchnick, who suggested that Bitcoin could become a "low-beta" asset if investor behaviour shifts accordingly, drawing from George Soros's reflexivity theory, where belief shapes reality.
Mitchnick's thesis is being supported by recent price action: Bitcoin held steady even as equities slid during renewed U.S.-China tensions. 
Notably, BTC was less volatile than the S&amp;P 500 over a 7-day stretch, while $3 billion flowed into spot ETFs. 
A growing share of long-term holders versus short-term traders may also be stabilizing the asset. 
While it's too early to definitively label Bitcoin low beta, the trend is drawing attention as investors seek diversification.
"If enough people believe BTC is low-beta, it may actually start behaving like one," said Puckrin.
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/25/05/45164011/bitcoin-ethereum-xrp-dogecoin-sentiment-rebounds-as-btc-hits-97000">Bitcoin, Ethereum, XRP, Dogecoin Sentiment Rebounds As BTC Hits $97,000</a>
Why It Matters: In a follow-up <a href="https://x.com/nicrypto/status/1918271016180302294">post</a> on May 2, Puckrin highlighted that altseason historically begins ~320 days after each halving. Key triggers still missing are:
<ul>
<li>Bitcoin dominance needs to fall below 54%, currently, it's still climbing.</li>
<li>ETH/BTC remains weak, lacking signs of a bottom.</li>
<li>The Fed must officially end Quantitative Tightening (QT) and signal rate cuts.</li>
</ul>
For altcoins to rally meaningfully, Bitcoin must break its all-time high without absorbing all the market's liquidity, Puckrin noted. 
Still, tailwinds are forming: stablecoin supply is expanding, often a precursor to broader crypto gains, regulatory pressure is easing — fewer enforcement actions, more ETF filings and Trump's recent executive order is seen as broadly pro-crypto.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/05/45168129/bitcoin-up-25-from-tariff-lows-heres-the-case-for-new-all-time-highs-soon">Bitcoin Up 25% From Tariff Lows: Here&#8217;s THe Case For New All-Time Highs Soon</a></li>
</ul>

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

Bitcoin Closing In On $100,000: What's Driving The Surge?

WIIM

Workiva shares are trading lower. The company issued Q2 Adj. EPS guidance below estimates.

DA Davidson analyst Wyatt Swanson maintains Duolingo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DUOL#NASDAQ">DUOL</a>) with a Buy and raises the price target from $410 to $470.

DUOL

DA Davidson Maintains Buy on Duolingo, Raises Price Target to $470

Mizuho analyst Ben Chaiken maintains Hilton Grand Vacations (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HGV#NYSE">HGV</a>) with a Outperform and raises the price target from $60 to $70.

Mizuho Maintains Outperform on Hilton Grand Vacations, Raises Price Target to $70

RBC Capital analyst Walter Spracklin maintains Canadian National Railway (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNI#NYSE">CNI</a>) with a Outperform and lowers the price target from $165 to $163.

RBC Capital Maintains Outperform on Canadian National Railway, Lowers Price Target to $163

iRhythm Technologies Inc&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRTC#NASDAQ">IRTC</a>) on Thursday reported first quarter 2025&nbsp;revenue of $158.7 million, up 20.3% year over year, beating the&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">consensus of $153.38 million</a>.
The increase was driven by growth in demand for Zio services.
The company reported an adjusted EPS loss of 95 cents, down from a loss of $1.23 a year ago, beating the <a target="_blank" href="https://www.benzinga.com/pressreleases/25/05/g45149802/irhythm-technologies-announces-first-quarter-2025-financial-results" rel="noreferrer noopener">consensus estimate of 98 cents</a>.
Gross profit was $109.2 million, up 24.8% from $87.5 million during the same period in 2024, while gross margin was 68.8%, up from 66.3% during the same period in 2024.
<ul>
<li>The increase in gross profit was primarily due to the increased volume of Zio services provided due to higher demand.</li>
<li>The increase in gross margin was primarily due to volume leverage and operational efficiencies, partially offset by an increased blended cost per unit from a higher Zio AT product mix.</li>
</ul>
Quentin Blackford, CEO of iRhythm, noted the company&#8217;s recent commercial launch in Japan for a total of six markets outside the U.S.
On Thursday, iRhythm announced the commercial launch of its Zio long-term continuous ECG monitoring (LTCM) system, commercially introduced in Japan as the Zio ECG <a href="https://www.benzinga.com/pressreleases/25/05/g45150321/irhythm-launches-zio-long-term-continuous-monitoring-service-in-japan-as-the-zio-ecg-recording-and" target="_blank" rel="noreferrer noopener">Recording and Analysis System</a>.
Guidance: iRhythm projects fiscal 2025 sales guidance of $690 million-$700 million, compared to prior guidance of $675 million-$685 million and consensus of $681.56 million.
William Blair writes, &#8220;We view updates this quarter as further validation of our thesis playing out this year as Zio AT accelerates, management executes on its land and expand strategy, and the company is seeing early positive signals in adjacent opportunities.&#8221;
<ul>
<li>Analyst Margaret Kaczor Andrew <a href="https://www.benzinga.com/quote/IRTC/analyst-ratings" target="_blank" rel="noreferrer noopener">maintains the Outperform rating</a>.</li>
<li>Wells Fargo upgrades iRhythm Technologies from Equal-Weight to Overweight, raising the price target from $104 to $130.</li>
<li>Baird maintains iRhythm with an Outperform rating, raising the price target from $133 to $150.</li>
<li>Needham maintains iRhythm with a Buy, raising the price target from $138 to $151.</li>
</ul>
Price Action: IRTC stock is up 19.1% at $129.37 at the last check Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/05/45167801/lendingtrees-mixed-q1-earnings-sharply-slashes-full-year-forecast-stocks-dive-premarket-friday" target="_blank" rel="noreferrer noopener">LendingTree&#8217;s Mixed Q1 Earnings: Sharply Slashes Full-Year Forecast, Stocks Dive Premarket Friday</a></li>
</ul>

Analyst Color

Earnings

Large Cap

Guidance

Health Care

Movers

Trading Ideas

General

IRTC

Zio Demand Drives 20% Revenue Growth For iRhythm, Bullish Sentiment Builds Among Analysts

Mizuho analyst David Bellinger maintains Floor &amp; Decor Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FND#NYSE">FND</a>) with a Neutral and lowers the price target from $100 to $80.

Mizuho Maintains Neutral on Floor & Decor Hldgs, Lowers Price Target to $80

RBC Capital analyst Walter Spracklin maintains Canadian National Railway (TSX:<a class="ticker" href="https://www.benzinga.com/stock/CNR#TSX">CNR</a>) with a Outperform and lowers the price target from C$165 to C$163.

TSX:CNR

RBC Capital Maintains Outperform on Canadian National Railway, Lowers Price Target to C$163

DA Davidson analyst Michael Shlisky maintains Oshkosh (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OSK#NYSE">OSK</a>) with a Buy and lowers the price target from $120 to $111.

DA Davidson Maintains Buy on Oshkosh, Lowers Price Target to $111

Mizuho analyst Ben Chaiken maintains Red Rock Resorts (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RRR#NASDAQ">RRR</a>) with a Neutral and lowers the price target from $52 to $50.

Mizuho Maintains Neutral on Red Rock Resorts, Lowers Price Target to $50

Roth MKM analyst George Kelly reiterates Carriage Servs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CSV#NYSE">CSV</a>) with a Buy and raises the price target from $48 to $51.

Reiteration

Roth MKM Reiterates Buy on Carriage Servs, Raises Price Target to $51

DA Davidson analyst Brent Thielman maintains Quanta Services (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PWR#NYSE">PWR</a>) with a Neutral and raises the price target from $295 to $305.

DA Davidson Maintains Neutral on Quanta Services, Raises Price Target to $305

Roth MKM analyst Scott Stember reiterates Patrick Industries (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PATK#NASDAQ">PATK</a>) with a Buy and lowers the price target from $112 to $100.

PATK

Roth MKM Reiterates Buy on Patrick Industries, Lowers Price Target to $100

RIOT

Riot Platforms shares are trading higher after the company reported better-than-expected Q1 sales results.

LMAT

LeMatire Vascular shares are trading lower after the company reported Q1 EPS guidance below estimates and lowered its FY25 EPS guidance.

In a world of increasingly divided markets between yield-hungry investors and adrenaline-seeking traders, Defiance ETFs is convinced there are some who want both. Meet the Defiance Leveraged Long + Income MSTR ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MST#NASDAQ">MST</a>), a recently introduced fund that combines leveraged long exposure to MicroStrategy Inc (Strategy) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>) stock with an unusual twist in the <a href="https://www.benzinga.com/etfs">world of geared ETFs</a> — weekly income.
It&#8217;s a high-wire performance: part momentum game, part revenue driver and all constructed around one of Wall Street&#8217;s most unstable surrogates for Bitcoin.
Also Read: <a href="https://www.benzinga.com/25/05/45149385/new-grayscale-etf-lets-you-invest-in-bitcoin-without-the-coin">New Grayscale ETF Lets You Invest In Bitcoin, Without The Coin</a>
<h1 class="wp-block-heading">A First-of-Its-Kind Structure</h1>
MST is the inaugural ETF to provide 1.5x to 2x daily exposure to MicroStrategy (Strategy) while at the same time attempting to distribute income weekly through a credit call spread method. It&#8217;s a structural spin designed to calm the volatile wildness of leveraged investing with the promise of regular, options-based payouts.
The dual aim of the fund — long-term capital growth and income generation — demonstrates increasing demand among retail investors for products that provide more than a simple directional gamble.
But <a href="https://www.globenewswire.com/news-release/2025/05/02/3073048/0/en/Defiance-ETFs-Unveils-MST-The-First-Leveraged-MicroStrategy-ETF-that-Seeks-to-Pay-Income-Weekly.html">MST </a>is not exactly a low-risk proposition: the levered element sees dramatic MicroStrategy (Strategy) movements working both ways, and the fund&#8217;s performance can stray from the mark when markets are volatile.
MST itself holds no cryptocurrencies, but its underlying stock of MicroStrategy (Strategy) is nominally a Bitcoin exposure vehicle masquerading as such. With Chairman Michael Saylor at the helm, the company has amassed billions of Bitcoin and now marches in near-lockstep with crypto sentiment. 
That makes MST, for good or bad, a means of playing Bitcoin&#8217;s upside (and downside) without actually holding the asset.
The firm bets on its success with previous MSTR-tied funds, the Daily Target 2X Long MSTR ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTX#NASDAQ">MSTX</a>) and the Daily Target 2X Short MSTR ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMST#NASDAQ">SMST</a>), which collectively have grown more than $1 billion in assets. MST extends the firm further into its theme of democratizing thematic, tactical ETFs to retail investors — without dumbing down the complexity.
But this is no sleepy index fund. The options overlay and dynamic leverage of the fund mean that investors have to remain vigilant to both reward and risk. MST can produce income and leverage returns — but in volatile markets, it can also leverage losses.
MST provides an unorthodox combination of crypto-adjacent leverage and weekly income, designed for risk-willing investors seeking to straddle momentum and cash flow. 
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/etfs/new-etfs/25/05/45153699/new-etf-bets-on-small-companies-to-offer-growth-monthly-income">New ETF Bets On Small Companies To Offer Growth, Monthly Income</a></li>
</ul>

New ETFs

ETFs

S&P Midcap 400 Index Capital Protected Notes 

MSTR

MSTX

SMST

New MST ETF Mixes MicroStrategy (Strategy) Leverage With A Side Of Weekly Income

Roth MKM analyst Philip Shen maintains FTC Solar (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTCI#NASDAQ">FTCI</a>) with a Neutral and raises the price target from $3 to $3.5.

FTCI

Roth MKM Maintains Neutral on FTC Solar, Raises Price Target to $3.5

RBC Capital analyst Douglas Miehm maintains Bausch Health Companies (TSX:<a class="ticker" href="https://www.benzinga.com/stock/BHC#TSX">BHC</a>) with a Sector Perform and raises the price target from C$8.5 to C$10.

TSX:BHC

RBC Capital Maintains Sector Perform on Bausch Health Companies, Raises Price Target to C$10

Roth MKM analyst Rohit Kulkarni maintains Reddit (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RDDT#NYSE">RDDT</a>) with a Neutral and raises the price target from $120 to $130.

RDDT

Roth MKM Maintains Neutral on Reddit, Raises Price Target to $130

Press Releases

Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Announce the First Patient Dosed in the Randomized, Presurgical Triple Negative Breast Cancer Phase 2 Clinical Trial (INVINCIBLE-4 / SAKK 66/22)

Intensity Therapeutics Selected for Oral Podium Presentation in a Late-Breaking Session at the 2024 Annual Connective Tissue Oncology Society (Sarcomas) Meeting

Intensity Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Intensity Therapeutics Presents INT230-6 Phase 1/2 Data in Sarcoma and an Overview of its Ongoing Global Randomized Phase 3 Sarcoma Trial ("INVINCIBLE-3 Study") in a Late-Breaking Session at the 2024 Annual Connective Tissue Oncology Society Meeting (CTOS)

Offerings

Intensity Therapeutics, Inc. Announces Pricing of $3 Million Registered Direct Offering and Concurrent Private Placement

Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Present Phase 2 Data in Presurgical Breast Cancer from the completed INVINCIBLE-2 Study, and an Overview of the Ongoing Randomized, Presurgical Triple Negative Breast Cancer Phase 2 Clinical Trial, INVINCIBLE-4 (SAKK 66/22), at the 2024 San Antonio Breast Cancer Symposium (SABCS)

Intensity Therapeutics Provides Business Update Highlighting Key Achievements with Lead Drug Candidate INT230-6

Drug Monitoring Committee Authorizes Continuation of Intensity Therapeutics' Ongoing Global Randomized Phase 3 Sarcoma Trial ("INVINCIBLE-3 Study") Following Periodic Review

Intensity Therapeutics Reports 2024 Year End Financial Results and Provides Corporate Update

Intensity Therapeutics, Inc. Announces $2.35 Million Public Offering

INTS

Acurx Pharmaceuticals, Inc. - Common Stock

Acurx Pharmaceuticals

Ainos

Apollomics Inc. - Class A Ordinary Shares

Apollomics

Aptorum Group Limited - Class A Ordinary Shares

Aptorum Gr

Aprea Therapeutics

Brainstorm Cell Therapeutics Inc. - Common Stock

Brainstorm Cell

bioAffinity Technologies, Inc. - Common Stock

bioAffinity Technologies

BioXcel Therapeutics, Inc. - Common Stock

BioXcel Therapeutics

Carisma Therapeutics, Inc. - Common Stock

CARISMA Therapeutics

Channel Therapeutics Corporation Common Stock

Channel Therapeutics

Cyclerion Therapeutics, Inc. - Common Stock

Cyclerion Therapeutics

Dogwood Therapeutics, Inc. - Common Stock

Dogwood Therapeutics

Evaxion Biotech A/S - American Depositary Share

Evaxion Biotech

HCW Biologics

iBio

Indaptus Therapeutics, Inc. - Common Stock

Indaptus Therapeutics

MetaVia

Mainz Biomed

Phio Pharmaceuticals Corp. - Common Stock

Phio Pharma

Polyrizon

PharmaCyte Biotech

Silexion Therapeutics Corp - Ordinary Shares

Silexion Therapeutics

Sensei Biotherapeutics, Inc. - Common Stock

Sensei Biotherapeutics

Turnstone Biologics

XTL Biopharmaceuticals Ltd. - American Depositary Shares

Comments

Intensity Therapeutics

뉴스

에 대한 최신 뉴스 Intensity Therapeutics (NASDAQ:INTS) 주식

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌